Roles of PI3K/AKT/PTEN pathway as a target for Pharmaceutical therapy

Open Medicinal Chemistry Journal

Volumn 7, Issue 1, 2013, Pages 23-29

  Matsuda, Satoru ^a   Nakanishi, Atsuko ^a   Wada, Yoko ^a   Kitagishi, Yasuko ^a  

^a NARA WOMEN'S UNIVERSITY   (Japan)

Author keywords

AKT; Cancer; mTOR; PI3K; PTEN; Signal transduction

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL) IMIDAZO [4, 5 C] QUINOLIN 2 (1H, 3H) ONE; 1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO [3', 2':4, 5] FURO [3, 2 D] PYRIMIDINE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; BAG 956; ETOPOSIDE; EVEROLIMUS; HALOPERIDOL; INITIATION FACTOR 4E; KP 372; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PERIFOSINE; PHOSPHATIDYLINOSITIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; S6 KINASE; UNCLASSIFIED DRUG; VALPROIC ACID; WORTMANNIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CIRCADIAN RHYTHM; DRUG DESIGN; GLYCOGEN SYNTHESIS; HUMAN; METABOLIC DISORDER; NEOPLASM; NEUROPROTECTION; NEUROTRANSMISSION; PNEUMONIA; PRIORITY JOURNAL; PROTEIN STRUCTURE; SCLEROSIS; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

EID: 84888020336     PISSN: None     EISSN: 18741045     Source Type: Journal    
DOI: 10.2174/1874104501307010023     Document Type: Article

References (61)

1. Sheppard, K.; Kinross, K. M.; Solomon, B.; Pearson, R. B.; Phillips, W. A. Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit. Rev. Oncog, 2012, 17, 69-95.
2. Foster, J. G.; Blunt, M. D.; Carter, E.; Ward, S. G. Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies. Pharmacol. Rev, 2012, 64, 1027-54.
3. Barrett, D.; Brown, V. I.; Grupp, S. A.; Teachey, D. T. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. Paediatr. Drugs, 2012, 14, 299-316.
4. Li, L.; Wei, X. H.; Pan, Y. P.; Li, H. C.; Yang, H.; He, Q. H.; Pang, Y.; Shan, Y.; Xiong, F. X.; Shao, G. Z.; Zhou, R. L. LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling. Oncogene, 2010, 29, 5785-95.
5. Choi, B. H.; Kim, C. G.; Lim, Y.; Shin, S. Y.; Lee, Y. H. Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway. Cancer Lett, 2008, 259, 111-8.
6. Sheppard, K.; Kinross, K. M.; Solomon, B.; Pearson, R. B.; Phillips, W. A. Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit. Rev. Oncog, 2012, 17, 69-95.
7. Okumura, N.; Yoshida, H.; Kitagishi, Y.; Murakami, M.; Nishimura, Y.; Matsuda, S. PI3K/AKT/PTEN Signaling as a Molecular Target in Leukemia Angiogenesis. Adv. Hematol, 2012, 2012, 843085.
8. Kirkegaard, T.; Witton, C. J.; Edwards, J. et al. Molecular alterations in AKT1, AKT2 and AKT3 detected in breast and prostatic cancer by FISH. Histopathology, 2010, 56, 203-11.
9. Hodgkinson, C. P.; Sale, E. M.; Sale, G. J. Characterization of PDK2 activity against protein kinase B gamma. Biochemistry, 2002, 41, 10351-9.
10. Bartolomé, A.; Guillén, C.; Benito, M. Role of the TSC1-TSC2 complex in the integration of insulin and glucose signaling involved in pancreatic beta-cell proliferation. Endocrinology, 2010, 151, 3084-94.
11. Jastrzebski, K.; Hannan, K. M.; Tchoubrieva, E. B.; Hannan, R. D.; Pearson, R. B. Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. Growth Factors, 2007, 25, 209-26.
12. Brand, C.; Cipok, M.; Attali, V.; Bak, A.; Sampson, S. R. Protein kinase Cdelta participates in insulin-induced activation of PKB via PDK1. Biochem. Biophys. Res. Commun, 2006, 349, 954-62.
13. Kim, Y. M.; Seo, Y. H.; Park, C. B.; Yoon, S. H.; Yoon, G. Roles of GSK3 in metabolic shift toward abnormal anabolism in cell senescence. Ann. N Y Acad. Sci, 2010, 1201, 65-71.
14. Al, Sweidi, S.; Sánchez, M. G.; Bourque, M.; Morissette, M.; Dluzen, D.; Di, Paolo, T. Oestrogen receptors and signalling pathways: implications for neuroprotective effects of sex steroids in Parkinson's disease. J. Neuroendocrinol, 2012, 24, 48-61.
15. Downes, C. P.; Perera, N.; Ross, S.; Leslie, N. R. Substrate specificity and acute regulation of the tumour suppressor phosphatase, PTEN. Biochem. Soc. Symp, 2007, 69-80.
16. Kong, D.; Yamori, T. Advances in development of phosphatidylinositol 3-kinase inhibitors. Curr. Med. Chem, 2009, 16, 2839-54.
17. Chen, Y.; Wang, S. M.; Wu, J. C.; Huang, S. H. Effects of PPARgamma agonists on cell survival and focal adhesions in a Chinese thyroid carcinoma cell line. J. Cell Biochem, 2006, 98, 1021-35.
18. Leslie, N. R.; Batty, I. H.; Maccario, H.; Davidson, L.; Downes, C. P. Understanding PTEN regulation: PIP2, polarity and protein stability. Oncogene, 2008, 27, 5464-76.
19. Rochet, J. C.; Hay, B. A.; Guo, M. Molecular insights into Parkinson's disease. Prog. Mol. Biol. Transl. Sci, 2012, 107, 125-88.
20. Yang, Y.; Gehrke, S.; Haque, M. E. et al. Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc. Natl. Acad. Sci. U S A, 2005, 102, 13670-5.
21. Murata, H.; Sakaguchi, M.; Jin, Y.; Sakaguchi, Y.; Futami, J.; Yamada, H.; Kataoka, K.; Huh, N. H. A new cytosolic pathway from a Parkinson disease-associated kinase, BRPK/PINK1: activation of AKT via mTORC2. J. Biol. Chem, 2011, 286, 7182-9.
22. Imai, Y.; Yamagishi, H.; Ono, Y.; Ueda, Y. Versatile inhibitory effects of the flavonoid-derived PI3K/Akt inhibitor, LY294002, on ATP-binding cassette transporters that characterize stem cells. Clin. Transl. Med, 2012, 1, 24.
23. El-Kholy, W.; Macdonald, P. E.; Lin, J. H.; Wang, J.; Fox, J. M.; Light, P. E.; Wang, Q.; Tsushima, R. G.; Wheeler, M. B. The phosphatidylinositol 3-kinase inhibitor LY294002 potently blocks K(V) currents via a direct mechanism. FASEB J, 2003, 17, 720-2.
24. Gross, E. R.; Peart, J. N.; Hsu, A. K.; Auchampach, J. A.; Gross, G. J. Extending the cardioprotective window using a novel delta-opioid agonist fentanyl isothiocyanate via the PI3-kinase pathway. Am. J. Physiol. Heart Circ. Physiol, 2005, 288, H2744-9.
25. Wolin, E. M. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors. Cancer Lett, 2013, 335, 1-8.
26. Gills, J. J.; Dennis, P. A. Perifosine: update on a novel Akt inhibitor. Curr. Oncol. Rep, 2009, 11, 102-10.
27. Srivastava, N.; Cho, D. C. Perifosine in renal cell carcinoma. Expert Opin. Investig. Drugs, 2013, 22, 285-91.
28. Ding, Q.; Gu, R.; Liang, J.; Zhang, X.; Chen, Y. PI-103 sensitizes acute myeloid leukemia stem cells to daunorubicin-induced cytotoxicity. Med. Oncol, 2013, 30, 395.
29. Yih, L. H.; Hsu, N. C.; Kuo, H. H.; Wu, Y. C. Inhibition of the heat shock response by PI103 enhances the cytotoxicity of arsenic trioxide. Toxicol. Sci, 2012, 128, 126-36.
30. Zeng, Z.; Samudio, I. J.; Zhang, W.; Estrov, Z.; Pelicano, H.; Harris, D.; Frolova, O.; Hail, N. Jr.; Chen, W.; Kornblau, S. M.; Huang, P.; Lu, Y.; Mills, G. B.; Andreeff, M.; Konopleva, M. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res, 2006, 66, 3737-46.
31. Mandal, M.; Younes, M.; Swan, E. A.; Jasser, S. A.; Doan, D.; Yigitbasi, O.; McMurphey, A.; Ludwick, J.; El-Naggar, A. K.; Bucana, C.; Mills, G. B.; Myers, J. N. The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell carcinoma of the head and neck. Oral. Oncol, 2006, 42, 430-9.
32. Romano, S.; Di, Pace, A.; Sorrentino, A.; Bisogni, R.; Sivero, L.; Romano, M. F. FK506 binding proteins as targets in anticancer therapy. Anticancer Agents Med. Chem, 2010, 10, 651-6.
33. Dibble, C. C.; Manning, B. D. Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat. Cell Biol, 2013, 15, 555-64.
34. Li, Z.; Yan, S.; Attayan, N.; Ramalingam, S.; Thiele, C. J. Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma. Clin. Cancer Res, 2012, 18, 3603-15.
35. Ishaq, K. S.; Capobianco, M.; Piantadosi, C.; Noseda, A.; Daniel, L. W.; Modest, E. J. Synthesis and biological evaluation of etherlinked derivatives of phosphatidylinositol. Pharm. Res, 1989, 6, 216-24.
36. Guo, Y.; Kwiatkowski, D. J. Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis. Mol. Cancer Res, 2013, 11, 467-73.
37. Ono, A.; Oike, R.; Okuhashi, Y.; Takahashi, Y.; Itoh, M.; Nara, N.; Tohda, S. Comparative effects of PP242 and rapamycin on mTOR signalling and NOTCH signalling in leukemia cells. Anticancer Res, 2013; 33, 809-13.
38. Weisberg, E.; Banerji, L.; Wright, R. D.; Barrett, R.; Ray, A.; Moreno, D.; Catley, L.; Jiang, J.; Hall-Meyers, E.; Sauveur-Michel, M.; Stone, R.; Galinsky, I.; Fox, E.; Kung, A. L.; Griffin, J. D. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL-and mutant FLT3-expressing cells. Blood, 2008, 111, 3723-34.
39. Mallon, R.; Feldberg, L. R.; Lucas, J.; Chaudhary, I.; Dehnhardt, C.; Santos, E. D,; Chen, Z.; dos Santos, O.; Ayral-Kaloustian, S.; Venkatesan, A.; Hollander, I. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. Clin. Cancer Res, 2011, 17, 3193-203.
40. Chapuis, N.; Tamburini, J.; Green, A. S.; Vignon, C.; Bardet, V.; Neyret, A.; Pannetier, M.; Willems, L.; Park, S.; Macone, A.; Maira, S. M.; Ifrah, N.; Dreyfus, F.; Herault, O.; Lacombe, C.; Mayeux, P.; Bouscary, D. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin. Cancer Res, 2010, 16, 5424-35.
41. Albiges, L.; Chamming's, F.; Duclos, B.; Stern, M.; Motzer, R. J.; Ravaud, A.; Camus, P. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann. Oncol, 2012, 23, 1943-53.
42. Kitagishi, Y.; Kobayashi, M.; Kikuta, K.; Matsuda, S. Roles of PI3K/AKT/GSK3/mTOR Pathway in Cell Signaling of Mental Illnesses. Depress Res. Treat, 2012, 2012, 752563.
43. Beaulieu, J. M.; Gainetdinov, R. R.; Caron, M. G. Akt/GSK3 signaling in the action of psychotropic drugs. Annu. Rev. Pharmacol. Toxicol, 2009, 49, 327-47.
44. Xu, J.; Li, C.; Yin, X. H.; Zhang, G. Y. Additive neuroprotection of GABA A and GABA B receptor agonists in cerebral ischemic injury via PI-3K/Akt pathway inhibiting the ASK1-JNK cascade. Neuropharmacology, 2008, 54, 1029-40.
45. Wang, L. L.; Ou, C. C.; Chan, J. Y. Receptor-independent activation of GABAergic neurotransmission and receptor-dependent nontranscriptional activation of phosphatidylinositol 3-kinase/protein kinase Akt pathway in short-term cardiovascular actions of dexamethasone at the nucleus tractus solitarii of the rat. Mol. Pharmacol, 2005, 67, 489-98.
46. Polter, A. M.; Yang, S.; Jope, R. S.; Li, X. Functional significance of glycogen synthase kinase-3 regulation by serotonin. Cell Signal, 2012, 24, 265-71.
47. Beaulieu, J. M.; Del'guidice, T.; Sotnikova, T. D.; Lemasson, M.; Gainetdinov, R. R. Beyond cAMP: The Regulation of Akt and GSK3 by Dopamine Receptors. Front Mol. Neurosci, 2011, 4, 38.
48. Chen, H. T.; Ruan, N. Y.; Chen, J. C.; Lin, T. Y. Dopamine D2 receptor-mediated Akt/PKB signalling: initiation by the D2S receptor and role in quinpirole-induced behavioural activation. ASN Neuro, 2012, 4, 371-82.
49. Emamian, E. S. AKT/GSK3 signaling pathway and schizophrenia. Front Mol. Neurosci, 2012, 5, 33.
50. Yun, S. I.; Yoon, H. Y.; Chung, Y. S. Glycogen synthase kinase-3beta regulates etoposide-induced apoptosis via Bcl-2 mediated caspase-3 activation in C3H10T1/2 cells. Apoptosis, 2009, 14, 771-7.
51. Liu, K. J.; Lee, Y. L.; Yang, Y. Y. et al. Modulation of the development of human monocyte-derived dendritic cells by lithium chloride. J. Cell Physiol, 2011, 226, 424-33.
52. Aisa, Y.; Miyakawa, Y.; Nakazato, T.; et al. Fucoidan induces apoptosis of human HS-sultan cells accompanied by activation of caspase-3 and down-regulation of ERK pathways. Am. J. Hematol, 2005, 78, 7-14.
53. Di, Daniel, E.; Cheng, L.; Maycox, P. R.; Mudge, A. W. The common inositol-reversible effect of mood stabilizers on neurons does not involve GSK3 inhibition, myo-inositol-1-phosphate synthase or the sodium-dependent myo-inositol transporters. Mol. Cell. Neurosci, 2006, 32, 27-36.
54. O'Brien, W. T.; Klein, P. S. Validating GSK3 as an in vivo target of lithium action. Biochem. Soc. Trans, 2009, 37, 1133-8.
55. Dal-Cim, T.; Molz, S.; Egea, J. et al. Guanosine protects human neuroblastoma SH-SY5Y cells against mitochondrial oxidative stress by inducing heme oxigenase-1 via PI3K/Akt/GSK-3 pathway. Neurochem. Int, 2012, 61, 397-404.
56. Molz, S.; Dal-Cim, T.; Budni, J.; Martín-de-Saavedra, M. D.; Egea, J.; Romero, A.; del Barrio, L.; Rodrigues, A. L.; López, M. G.; Tasca, C. I. Neuroprotective effect of guanosine against glutamateinduced cell death in rat hippocampal slices is mediated by the phosphatidylinositol-3 kinase/Akt/glycogen synthase kinase 3 pathway activation and inducible nitric oxide synthase inhibition. J. Neurosci. Res, 2011, 89, 1400-8.
57. Kim, J. Y. Control of ovarian primordial follicle activation. Clin. Exp. Reprod. Med, 2012, 39, 10-4.
58. Reddy, P.; Liu, L.; Adhikari, D.; Jagarlamudi, K.; Rajareddy, S.; Shen, Y.; Du, C.; Tang, W.; Hämäläinen, T.; Peng, S. L.; Lan, Z. J.; Cooney, A. J.; Huhtaniemi, I.; Liu, K. Oocyte-specific deletion of Pten causes premature activation of the primordial follicle pool. Science, 2008, 319, 611-3.
59. Li, J.; Kawamura, K.; Cheng, Y.; Liu, S.; Klein, C.; Liu, S.; Duan, E. K.; Hsueh, A. J. Activation of dormant ovarian follicles to generate mature eggs. Proc. Natl. Acad. Sci. U S A, 2010, 107, 10280-4.
60. Fox, T. E.; Young, M. M.; Pedersen, M. M.; Han, X.; Gardner, T. W.; Kester, M. Diabetes diminishes phosphatidic acid in the retina: a putative mediator for reduced mTOR signaling and increased neuronal cell death. Invest. Ophthalmol. Vis. Sci, 2012, 53, 7257-67.
61. Cai, J.; Ahmad, S.; Jiang, W. G.; Huang, J.; Kontos, C. D.; Boulton, M.; Ahmed, A. Activation of vascular endothelial growth factor receptor-1 sustains angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-kinase pathway in endothelial cells. Diabetes, 2003, 52, 2959-68.